Program

Preliminary program now available!

The APLAR 2023 official program is scheduled in the Chiang Mai time zone (GMT+7). To check the program times in your location, use our time zone converter.

As more information becomes available – this page will be updated so please make sure to check back regularly.

Thurs 7 Dec
Workshops
Fri 8 Dec
Workshops
Sat 9 Dec
Congress Day 1
Sun 10 Dec
Congress Day 2
Mon 11 Dec
Congress Day 3


0800	REGISTRATION
0830-0900	1st APLAR Endorsed Course of Musculoskeletal Ultrasound Workshop – basic level \| Day 1 Workshop begins at 0830. View information here
0900-1200		MRI Axial Imaging Course Course begins at 0900. View information here
1200-1245	BREAK
1245-1445	1st APLAR Endorsed Course of Musculoskeletal Ultrasound Workshop – basic level \| Day 1 Continued	MRI Axial Imaging Course Continued
1445-1515	BREAK
1515-1700	1st APLAR Endorsed Course of Musculoskeletal Ultrasound Workshop – basic level \| Day 1 Continued - Workshop finishes at 1700 for this day.	MRI Axial Imaging Course Course finishes at 1600.


0800-0830	REGISTRATION
0830-0900	1st APLAR Endorsed Course of Musculoskeletal Ultrasound Workshop – basic level \| Day 2 Continued - Workshop begins at 0830. View information here
0900-1000				mRSS Assessment Course Course will run between 0900 - 1015 before the break View Information here
1000 -1030	BREAK
1030 -1200	1st APLAR Endorsed Course of Musculoskeletal Ultrasound Workshop – basic level \| Day 2 Continued			mRSS Assessment Course Course finishes at 1200, noon
1200 -1245	BREAK
1245 -1400	1st APLAR Endorsed Course of Musculoskeletal Ultrasound Workshop – basic level \| Day 2 Continued	AYR Clinical Skills workshop -labial salivary gland biopsy and muscle biopsy View information here	GRAPPA Symposium Symposium begins at 1330. View information here	mRSS Assessment Course - REPEATED COURSE Course begins at 1330. View Information here
1430 -1500	BREAK
1500 -1630	1st APLAR Endorsed Course of Musculoskeletal Ultrasound Workshop – basic level \| Day 2 Continued - Workshop continues until 1700.	Changing and perspective of academic journals View information here	GRAPPA Symposium Symposium finishes at 1630.	mRSS Assessment Course - REPEATED COURSE Course finishes at 1630
1700-1800	Opening Ceremony Included in registration. View more information here
1800-1930	Welcome Reception and Official Opening of Exhibition Hall Included in registration. View more information here

ROOM Capacity	B7 150 theatre capacity	B2 50 classroom capacity	B8 150 classroom capacity	B9 250 theatre capacity	B3 100 classroom capacity	B4 100 classroom capacity	B5 100 classroom capacity	A2 30 u-shape
0830-0900	REGISTRATION
0900-1000	Cont. MSUS Workshop Day 2	Cont. MRI Imaging Course Day 2	GRAPPA Symposium	Allied Health Course	APLAR Industry workshop 1 set up	APLAR Industry workshop 2 set up	APLAR Industry workshop 3 set up	APLAR Executive Committee Meeting
1000 -1030	COFFEE BREAK							COFFEE BREAK
1030 -1200	Cont. MSUS Workshop Day 2	Cont. MRI Imaging Course Day 2	Cont. GRAPPA Symposium	Cont. Allied Health Course				APLAR Meetings
1200 -1245	LUNCH BREAK							LUNCH BREAK
1245 -1400	Cont. MSUS Workshop Day 2	Cont. MRI Imaging Course Day 2	Cont. GRAPPA Symposium	Cont. Allied Health Course				APLAR Meetings
1400-1700					AFTERNOON TEA
1400-1700					Industry pre-congress workshop 1	Industry pre-congress workshop 2	Industry pre-congress workshop 3	APLAR Meetings
ROOM Capacity	PLENARY/CONCURRENT 1 - Exhibition Hall 1 2,000 capacity
1700-1800	Opening Ceremony
ROOM Capacity	Exhibition Hall 3 - exhibition
1800-1930	Welcome Reception and Official Opening of Exhibition Hall


0800-0930	Plenary session 1
0800-0930	Chairpersons: Catherine Hill and Masayoshi Harigai Insights into the paradoxical effect of smoking on Behcet's disease Alireza Khabbazi TNF inhibitors and JAK inhibitors:which is better for relapsed Takayasu's arteritis Xinping Tian Geo-ethnic variations in vasculitis disease Debashish Danda
0930-1030	Plenary session 2
0930-1030	Chairpersons: Ho So and Ajchara Koolvisoot What do we learn about the nature of scleroderma disease from the EU-US and Asia-Pacific database? Andrea Low Update of guidelines on treatments of interstitial lung disease in connective tissue diseases from ERS/EULAR Oliver Distler
1030-1055	BREAK AND POSTER VIEWING
1055-1200	Morning symposium 1
1055-1200	For industry program information click here
1200-1315	Concurrent sessions
	SpA / PsA session Chairpersons: Nazrul Islam and Muhammad Ahmed Saeed	Large vessel vasculitis 2023 update Coordinated by the APLAR Vasculitis SIG Chairpersons: Debashish Danda and Farzana Shumy	Scleroderma session Coordinated by the APLAR Scleroderma SIG Chairpersons: Andrea Low and Jasmin Raja	Insight antiphospholipid syndrome and associated diseases Chairpersons: Sami Salmon and Kenji Oku	Abstract session: late breaking 1 Chairpersons: Claire Barrett and Galymzhan Togizbayev
	Juvenile SpA: pathogenisis, assessment and outcome Amita Aggarwal Gut dysbiosis in axial spondyloarthritis Hong Ki Min Novel treatment algorithms in axial spondyloarthritis - what is the current status? Xenofon Baraliakos Q&A	Opening remarks Farzana Shumy Epidemiology and clinical features of GCA Catherine Hill Management of GCA Frank Butthereit Takayasu arteritis and reproduction Takako Miyamae Panel discussion Catherine Hill, Frank Butthereit, Takako Miyamae and Masayoshi Harigai Closing remarks Debashish Danda	Novel therapies in SSc and lessons learnt from clinical trials Oliver Distler Bridging the valley of death from bench to bedside in systemic sclerosis Tohru Takeuchi Q&A A challenging therapeutic case of SSc panel discussion ChingChing Foocharoen, Oliver Distler and Tohru Takeuchi	Update in pathogenesis and relevance antibodies Takao Koike Controversy of APS in SLE Laniyati Hamijoyo Clinical features and treatments in interferon-driven APS-SLE Yoshiya Tanaka	Circulating Plasma derived exosomes from Systemic Lupus Erythematosus aggravate lupus nephritis through miR-122-5p/FOXO3-mediated macrophage activation Juan Ji Overexpression of miR-20a-5p in mesenchymal stem cell exosomes from systemic lupus erythematosus patients restored therapeutic effect and Treg immune regulation Juan Ji Efficacy and Safety of Low-Dose Interleukin 2 for Behçet’s Syndrome：A Randomized Controlled Trial Tian Liu Correlation of Pulmonary Function test and Automated CT analysis by CALIPER in CTD-related ILD: A Cross-Sectional Study Aditi Patankar Serum alpha-1 antitrypsin in diagnosis and prognosis of antiphospholipid syndrome Yuebing Wang Serial imaging changes in skeletal muscle composition and their association with clinical outcomes in idiopathic inflammatory myopathies Chengappa Kavadichanda
1315-1435	Lunch symposium 1	BREAK AND POSTER VIEWING			Meet the Expert 1
1315-1435	For industry program information click here.	BREAK AND POSTER VIEWING			Chairperson: Tasanee Kitumnuaypong (F, Thailand) and Jerusha Naidoo Unmet needs in SLE Alberta Hoi Sponsored by GSK
1435-1550	Concurrent sessions
	Axial manifestation of psoriatic arthritis Chairpersons: Sang-Heon Lee and Praveena Chiowchanwisawakit	Myositis session Coordinated by the APLAR myositis SIG Chairpersons: Iris Tang and Takahisa Gono	Paedatric rheumatology workforce: fill the gap session Coordinated by the APLAR Paediatric SIG Chairpersons: Caifeng Li and Elizabeth Ang	Genetics session Coordinated by the APLAR Genetics SIG Chairpersons: Michael Tee and Chikashi Terao	Abstract session: late breaking 2 Chairpersons: Hung Nguyen and Kanon Jatuworapruk
	Clinical features of axial manifestation of psoriatic arthritis Ved Chaturvedi The immune landscapes of psoriatic arthritis Katy Leung Treatment of axial PsA Lai-Shan Tam	Myositis related ILD: from bench to bedside Takuya Kotani Improving IIM classification criteria: where are we now? Jessica Day Myositis histopathology: what clinicians need to know Xin Lu Q&A	Opening remarks Innovations in training Sirirat Charuvanij Models of e-learning RAJ Masaki Shimizu How to treat series: on-line courses Kowsar Asna Ashari COE: blueprint for lesser mortals Surjit Singh Q&A	Genetic approach to identify new targeted therapies in SLE Prapaporn Pisitkun Personalised medicine in rheumatology: leveraging genetic insights to disease predict Yi-Ming Chen Genetic polymorphism in rheumatoid arthritis Suleman Khan Q&A	Ultrasound as noninvasive procedure for the diagnosis of Calcium Pyrophosphate Deposition Disease: a new window Farzana Shumy Long non-coding RNA ITGB8-AS1 inhibits rheumatoid arthritis synovial inflammation by negatively regulating TGFβ/RAC1 pathway Yipeng Han Overexpression of IFNγ Genes Identified by Single-Cell Transcriptomics in Patients with Rheumatoid Arthritis Hyoun Kim Immune-metabolic Heterogeneity and Clinical Implications in Primary Sjogren's Syndrome Revealed by Molecular Classification of Salivary Glands Huji Xu Characteristics of dry eye with autoimmune features (DEAF): a cross-sectional study of a single center Zeng Yuqing
1550-1615	BREAK AND POSTER VIEWING
1615-1730	Concurrent sessions
	EULAR session: Early diagnosis and management of arthritis Chairpersons: Yoshiya Tanaka	Clinical immunology and rheumatology Coordinated by the AYR SIG Chairpersons: Priscilla Wong and Himantha Atukorale	Rheumatology potpourri 1 Chairpersons: Steven Sawyers and Nuntana Kasitanon	Women's Health & Reproductive Issues in RMDs Coordinated by the Reproductive SIG Chairpersons: Rohini Handa and Saira Khan	Abstract session: late breaking 3 Chairperson: Hung Nguyen and Worawit Louthrenoo
	A journey through recent EULAR management recommendations Anna-Maria Iagnocco Early RA diagnosis - where are we now? Daniel Aletaha Modern imaging tools for early SpA diagnosis Xenofon Baraliakos Q&A	Immunodeficiencies presenting to the rheumatology clinic Justina Tan Updates in immunoglobulin replacement Valerie Chiang A novel approach to anti-cytokine sydnromes - when autoimmunity presents as infections out of the blue Xin Li Q&A	Biomarker and immunology aspect in fibromyalgia Geoffrey Littlejohn Metabolomic in rheumatic diseases Ramnath Misra Sleep disorders in rheumatic diseases Zhifeng Gu	Introduction into pregnancy and rheumatic disease with focus on SLE and APLS Samar Al-Emadi Inflammatory arthritis including RA, SpA (efect of the disease on pregnancy and fetal comes) Mu Rong Safety of medication during pregnancy and lactations Alberta Hoi Q&A	Evaluating Distinct T Cell Subset Levels and Their Post-Treatment Dynamics as Potential Biomarkers for Immune-Related Adverse Events in Immunotherapy Yifan Wang Lymphatic vessels drain monosodium urate and involve in the regression of gouty arthritis Luying Yuan Shentong Zhuyu Decoction Alleviates Gouty Arthritis Through Inhibiting MAPK/NLRP3/IL-1β Signaling Pathway Luying Yuan Machine learning in clinical predictive models for infection of lupus nephritis Jiaqian Zhang Response of low dose IL2 in patients with systemic lupus erythematosus---a real-word study Ruiling Feng Real-world Safety and Effectiveness of SB5 (adalimumab biosimilar) for Rheumatic Diseases in South Korea: A Real-world Post-marketing Surveillance Interim Data Yoon-Kyoung Sung Development of a list of autoimmune rheumatic diseases and their manifestations for population screening: a consensus development study Ling Xiang
1745-1845		Evening symposium 2
1745-1845		For industry program information click here

ROOM Capacity	Exhibition Hall 1 2,000 capacity	Convention Hall 1 1,700 capacity	Leelawadee Hall 1 400 theatre capacity	Leelawadee Hall 2 400 theatre capacity	B1 100 theatre capacity	Exhibition Hall 3
0800-0900
0900-1030
1030-1055							BREAK AND POSTER VIEWING
1055-1200	Morning symposium 1 Sponsored by AbbVie	Morning symposium 2	Morning symposium 3	Morning symposium 4
1200-1315	Concurrent session SIG Rheumatoid arthritis	Concurrent session SIG Vasculitis	Concurrent session COVID-19 infection and rheumatic diseases	Concurrent session Personalized treatment in idiopathic inflammatory myopathy (IIM)	Concurrent session SIG Sjogren
1315-1435	Lunch symposium 1 Sponsored by Pfizer	Lunch symposium 2				1320-1350 Meet the experts 1 Sponsored by GSK
1315-1435	Lunch symposium 1 Sponsored by Pfizer	Lunch symposium 2				1400-1430 Meet the experts 2 Sponsored by Boehringer Ingelheim
1435-1550	Concurrent session 1. Update treatment in osteoporosis Sequential and combination of osteoporosis therapy Denosumab discontinuation 2.Osteoporosis treatment and cardiovascular effects Relationship of bone and cardiovascular system Cardiovascular effects of osteoporosis therapies	Concurrent session SIG Myositis Update on idiopathic inflammatory myopathy diagnosis From pathology to diagnosis Myositis specific antibodies in IIM and clinical relevance	Concurrent session SIG Pediatric Children with rheumatic diseases during COVID-19 era Immunogenicity and effectiveness of COVID-19 vaccination Outcomes of autoimmune diseases after COVID-19 infection/vaccination	Concurrent session IgG4 related disease Updated mechanisms Perspective treatment Myositis specific antibodies in IIM and clinical relevance


0800-0900	Concurrent sessions
	Advanced therapy in rheumatic diseases Chairpersons: Lai-Shan Tam and Andrea Low	Abstract session 1: Antiphospholipid syndrome Chairperson: Pintip Ngamajanyaporn	Abstract session 2: Autoinflammatory disease / paediatric Chairperson: Soamarat Vilaiyuk	Abstract session 3: Miscellaneous Chairperson: Chit Soe
	Treatment of non-radiographic axial spondyloarthritis: which kinds of medicine should be the most appropriate treatment for non-radiographic axial spondyloarthritis and when to start? Mitsumasa Kishimoto Q&A Advances in targeted therapy in rheumatic diseases Anna-Maria Hoffmann Vold Q&A	The Subtype and Prognosis of Acute Myocardial Infarction in Antiphospholipid Syndrome patients Can Huang Plasma lipidomics analysis reveals the distinguishing pathogenesis between arterial and venous thrombosis in patients with antiphospholipid syndrome Hui Jiang Characterization of B-Cell Subsets in Antiphospholipid Syndrome Patients: Implications for Disease Phenotype and Pathogenesis Yin Long Cluster analysis of antiphospholipid antibodies associated adverse pregnancy outcome patients: based on a 13-year longitudinal cohort study Yin Long Oxidized Low-Density Lipoprotein and antibodies against Oxidized Low-Density Lipoprotein in Patients With Antiphospholipid Syndrome Yongjing Luo	Presenting Features of Rheumatic diseases in Children- Single Center Experience from western India Deepti Agarwal The safety and efficacy of canakinumab treatment for undifferentiated autoinflammatory diseases: the data of retrospective cohort two-centered study Mikhail Kostik The diagnostic cut-off for discrimination of nonbacterial osteomyelitis from other bone destructive diseases Mikhail Kostik The proximity-enabled covalent binding of IL-2 to IL-2Rα selectively and persistently augments its effects on Tregs and suppresses autoimmune pathologies Yeting Sun Paxlovid use is associated with lower risk of cardiovascular diseases in COVID-19 patients with rheumatic diseases: a retrospective cohort study Weijie Wang Chronic Recurrent Multifocal Osteomyelitis (CRMO) in a tertiary center in Iran; a case series and review of the literature Kosar Asna Ashari	Machine Learning Models Identify Gut Microbiota that Predict Chronicity in Reactive Arthritis Sakir Ahmed Risk Factors for Plantar Fasciitis: A Case Control Study Among Patients Attending Rheumatology Clinic Anushka Ediriweera The Largest Asian GWAS and the HLA Study for Systemic Sclerosis Identified a Novel High-Risk Locus and the HLA-DRB1 Association Yuki Ishikawa Serum uric acid and lung function in NHANES dated from 2007 to 2012: A cross-sectional research Tianlun Kang Deep Learning Approaches to Rheumatoid Arthritis Severity Prognosis Isaac Zachary To Clinical prediction score of sustained remission to methotrexate therapy in patients with early rheumatoid arthritis Sujin Lertwises
0900-1030	Plenary session 3
0900-1030	Chairpersons: Rohini Handa and Yi-Hsing Chen Rational DMARDs use in Asian context Tsutomu Takeuchi How to taper and/or discontinue DMARDs (csDMARDs, biologics and JAKi) in RA patients with sustained remission Daniel Aletaha Non-selective vs selective JAK inhibitors for RA: effectiveness and safety Peter Nash
1030-1100	BREAK AND POSTER VIEWING
1100-1200	Concurrent sessions
	Deep insight in SLE Chairpersons: Atsushi Kawakami and Prapaporn Pisitkun	Personalized treatment in idiopathic inflammatory myopathy (IIM) Chairpersons: Latika Gupta and Jasmin Raja	Rheumatology Potpourri 2 Chairpersons: Yi-Hsing Chen and Nuntana Kasitanon	Abstract session 4: Osteoarthritis / Osteoporosis / Crystal arthropathies Chairperson: Kanon Jatuworapruk
	Optimising glucocorticoid therapy in SLE Sandra Navarra Q&A Insight biologic therapy in SLE Yoshiya Tanaka Q&A Measuring disease activity in lupus clinical trials: finding the right metrics for success Eric Morand Q&A	IIM associated ILD Hideaki Tsuji What's new in anti-MDA5 dermatomyositis? Ho So	Renal and neurological problems in Sjogren's syndrome Sandhya Pulukool Imaging in large vessel vasculitis Naoto Tamura	Comparative Effectiveness of Yoga and Strengthening Exercise for Treating Knee OsteoArthritis: A Randomised Controlled Trial (YOGA Trial) Benny Antony Reconstruction of the intra-articular environment of osteoarthritis in a 3d co-culture system Gunil Im Causal Relationships Between Body Mass Index and Osteoarthritis Disease: A Bidirectional Mendelian Randomization Study Feng Jiang HU values from vertebral CT for the diagnosis of osteoporosis: a systematic review and meta-analysis Feng Jiang A double-blinded randomized controlled study comparing non-loading versus loading low-dose oral colchicine in acute crystal-associated arthritis Ployrung Laosuksri Novel insights into the osteoclast regulatory system Masayuki Tsukasaki
1200-1315	Concurrent sessions
	Osteoarthritis session Coordinated with the APLAR Osteoarthritis SIG Chairpersons: Keith Lim and Sumapa Chaiamnuay	Recent advances in psoriatic arthritis Coordinated by the APLAR SpA SIG Chairpersons: Nizar Abdulateef Jassim and Kichul Shin	Social commitment and patient outreach session Coordinated by the Social commitment and patient outreach SIG Chairpersons: Syed Atiqul Haq and Nighat Ahmad	Abstract session 5: Rheumatoid Arthritis Chairperson: Wunrachada Katchamart
	Joint effusions and knee OA Keith Lim Inflammatory phenotype of osteoarthritis and potential therapies Changhai Ding Predictors of clinical response8 in osteoarthritis Benny Antony Q&A	State of the art therapeutics for PsA Lai-Shan Tam Precision medicine in predicting treatment response in psoriatic arthritis Ippei Miyagawa Role of MRI in PsA Ashish Mathew Q&A	Introduction Syed Atiqul Haq and Nighat Ahmad Educating patients: show should a rheumatology proceed A T M Tanveer Hasan The HomeRheum Status: Current state of rheumatology workforce in Asia-Pacific Jonathan Paul Consignado Q&A Closing remarks Syed Atiqul Haq and Nighat Ahmad	Significant association of plasma levels of galectin-9 and soluble TIM-3 with non-alcoholic fatty liver disease in patients with rheumatoid arthritis Po-Ku Chen Whole-exome sequencing revealed variants of NLR-related and SLX-related genes as predictors of remission with tofacitinib therapy in rheumatoid arthritis patients Der-yuan Chen Fatty acid synthase is a critical repressor of ferroptosis in rheumatoid arthritis Qi Cheng 25-hydroxycholesterol in the pathogenesis of rheumatoid arthritis Hong Huang Immunophenotyping of rheumatoid arthritis (RA) stratifies five subgroups and reveals pathogenic CD4 T cell subset Satoshi Kubo Synovial tissue heterogeneity and predominant inflammatory signal in Japanese patients with rheumatoid arthritis Sotaro Nakajima Novel associations between fibroblast growth factor 23 levels and RF and IFN-γ in rheumatoid arthritis Ryu Watanabe
1315-1435
	Lunch symposium 3	BREAK AND POSTER VIEWING
	For industry program information click here	BREAK AND POSTER VIEWING
1435-1550	Concurrent sessions
	Best management of SLE Coordinated by the SLE SIG Chairpersons: CC Mok and Yoshiya Tanaka	Rheumatoid arthritis session Coordinated by the RA SIG Chairpersons: Kunihiro Yamaoka and Zhanguo Li	Emerging treatment strategies for osteoporosis Coordinated by the Osteoporosis SIG Chairpersons: Lau Tang Ching and Sumapa Chaiamnuay	Abstract session: Late breaking 4 Chairperson: Emmanuel C. Perez
	Impact of ethnic and social inequity on outcome of SLE Sarfaraz Hasni Assessment of disease activity of SLE Kathryn Connelly COVID-19 in SLE Syahrul Sazliyana Q&A	Recommendation update Kunihiro Yamaoka Improvement of early diagnosis and management of rheumatoid arthritis using digital health system Chun Li Q&A	What is hot and what is not in bone? Kenneth Saag Case discussion on sequential vs combination therapy Julie Yu Debate - treat or target for osteoporosis, myth or reality? Lau Tang Ching and Sumapa Chaiamnuay Q&A	Consensus Recommendations for Referral, Diagnosis, Monitoring, and Management of Axial Spondyloarthritis in the Gulf Countries Khalid Alnaqbi Efficacy and Safety of Tofacitinib in the Treatment of NSAIDs-Refractory Axial Spondyloarthritis: A Clinical Trial Md Nahiduzzamane Shazzad Effectiveness and safety of upadacitinib in patients with active ankylosing spondylitis: results from the Russian registry racurs Tatiana Dubinina Efficacy of oral steriods for peripheral arthritis in spondylarthritis: a double blind, parallel group, randomised control trial Sankar Jayaprakash Germanium Telluride-Polyvinylpyrrolidone Nanosheets ameliorate inflammatory response in inflammatory disease model Yong-Beom Park Transforming Calcinosis in Juvenile dermatomyositis: Tofacitinib’s impact- A case series Anand Sasidharan
1550-1620	BREAK AND POSTER VIEWING
1620-1735	Concurrent sessions
	Current evidence of osteoarthritis management Chairpersons: Nazrul Islam and Keith Lim	Digital health and clinical decision support system in rheumatology Best management of SLE Coordinated by the Digital Health and Telemedicine SIG Chairpersons: Yew Kuang Cheng and Anindita Santosa	Crystal induced arthritis session Coordinated by the Crystal induced arthritis SIG Chairpersons: Helen Keen and Jose Paulo Lorenzo	Abstract session 7: Systemic lupus erythematosus Chairperson: Rattapol Pakchotanon
	Update pathogenesis of osteoarthritis Inoshi Atukorala Update treatment in osteoarthritis Syed Atiqul Haq What's new in hand osteoarthritis? Benny Antony	Why should we use artificial intelligence in rheumatic disease? Sakir Ahmed Artificial intelligence implication in rheumatic diseases Lisa Traboco Q&A	The intersection of gout and chronic kidney disease Evelyn Salido Gaps in the current knowledge of evaluation and treatment of gout Binit Vaidya CPPD the ignored disease Sami Salmon APLAR gout registry updates and preliminary results Kanon Jatuworapruk Q&A	The Impact of Antiphospholipid Antibodies on Future Atherosclerotic Cardiovascular Disease Risk in Systemic Lupus Erythematosus Yufang Ding Cluster Analysis Reveals Subgroups in Patients with Serologically Active Clinically Quiescent Systemic Lupus Erythematosus: Implication for Long-term Prognosis Prediction Yufang Ding Taiwan Consensus Recommendations on the Management of Systemic Lupus Erythematosus Wen-Nan Huang Can KidneyHistopathology predict disease flares following drug withdrawal in Proliferative LupusNephritis?Subgroup analysis of a Randomised drug withdrawal trial in SLE Chengappa Kavadichanda Antiphospholipid Antibodies As Potential Predictors Of Disease Severity And Poor Prognosis In Systemic Lupus Erythematosus Associated Thrombocytopenia Jun Li Climate Change and Haze in Malaysia: Impact on Systemic Lupus Erythematosus (SLE) disease activity Shaharir Syahrul Sazliyana Efficacy and Safety of ABBV-599 High Dose and Upadacitinib Monotherapy for Systemic Lupus Erythematosus: A Phase 2 Trial Yoshiya Tanaka
1735-1850	Concurrent sessions
	Gout in women Chairpersons: Jose Paulo Lorenzo and Worawit Louthrenoo	Pain in rheumatic musculoskeletal disorders: A COPCORD perspective Coordinated by the Epidemiology COPCORD SIG Chairpersons: Arvind Chopra and Samar Al-Emadi	Chronic pain session Coordinated by the Chronic pain SIG	Abstract session 8: Spondylarthropathies Chairperson: Samina Ghaznavi
	Urate biology Helen Keen Clinical presentations and management Monika De Silva Patient preferences in gout management Jisoo Lee	What a pain it is! Arvind Chopra Pain beyond inflammation in rheumatic disorders Shin-Seok Lee Lessons on capturing pain from COPCORD studies Leonila Dans Epidemiology of fibromyalgia in rheumatic diseases Soosan Soroosh Sex differences in perception of pain in the COPCORD domain Binit Vaidya Future COPCORD research agenda for pain in rheumatic diseases Ashish Mathew Q&A	Chronic Musculoskeletal pain in Diabetes malitus- a spectrum with a difference Sabrina Yesmin Fibromyalgia, then and now Sundeep Upadhyaya Community based study of prevalence and social factors for chronic pain and fibromyalgia in women from western India Sandeep Kansurkar Q&A	Real-World Switching and Discontinuation Patterns for Biologic Disease-Modifying Antirheumatic Drugs in Patients With Active Psoriatic Arthritis in Japan Momoko Inoue Value of low-dose computed tomography for examination of sacroiliac joints in axial spondyloarthritis In-woon Baek Are we treating-to-target in spondyloarthritis(SpA)? A one-year analysis from the Asia Pacific League of Associations for Rheumatology (APLAR) SpA Registry Isaac T Cheng Utility of a multi-biomarkers panel on predicting disease activity in patients with psoriatic arthritis – a derivation and validation study Yingzhao Jin Domains Impacting Minimal Disease Activity Non-achievement in Patients with Psoriatic Arthritis and Inadequate Response to TNFi Receiving Guselkumab (COSMOS) Kevin Pile Performance of various definitions for active MRI lesions in sacroiliac joint and spine in discriminating patients with axial psoriatic arthritis Xianfeng Yan Bimekizumab in the Chinese Subpopulation of Patients with Active Radiographic Axial Spondyloarthritis: 52-Week Results from BE MOBILE 2 Huji Xu
1930-2130	Joint Presidential & Gala Dinner Not included in registration. Tickets available at additional cost. View more information and registration information here


0800-0900	Concurrent sessions
	Gout session Chairpersons: Helen Keen and Ronald Yip	Relapse of adult-onset Still disease Chairpersons: Wafa Wadanat and Samar Al-Emadi	Abstract session 9: Systemic vasculitis / Sjogren syndrome Chairpersons: Alakendu Ghosh and Pichaya O-Charoen	Abstract session 10: Scleroderma / Myositis Chairpersons: Uma Kumar and Chayawee Muangchan
	Cardiovascular morbidity in gout Jose Paulo Lorenzo Emerging strategies for treating difficult gout Worawit Louthrenoo	Genetics and risk factors Alireza Khabbazi How to treat and efficacy of tight control Dae Hyun Yoo	Fecal Calprotectin and the Complications of Immunoglobulin (Ig)A-mediated vasculitis: A Cross-sectional Study Elaheh Baharvand Ahmadi Deltex1, a T cell anergy regulator, may be a biomarker of disease activity in Sjögren’s syndrome Ming-Han Chen Risk factors for serious infections and infection-related mortality in patients with microscopic polyangiitis: a multicenter retrospective observational cohort study Atsushi Manabe Lysosome-associated membrane protein 3 expression is involved in enhanced type I interferon response in Sjögren’s syndrome Hiroyuk Nakamura Real-world Effectiveness of Interleukin-6 Receptor Inhibitors in patients with Steroid Refractory Polymyalgia Rheumatica Hubert van Hoogstraten Sustained Remission From Weeks 16 and 24 to Week 52 in Patients With Polymyalgia Rheumatica Receiving Sarilumab: SAPHYR Post-hoc Analysis Hubert van Hoogstraten	Developing a Screening Tool for the Detection of Interstitial Lung Disease in Systemic Sclerosis: the ILD-RISC Score Oliver Distler Consistency between enzyme-linked immunosorbent assay and line blot assay in myositis-specific autoantibody in patients with Idiopathic inflammatory myopathies Takahisa Gono Interstitial Lung Diseases Among Idiopathic Inflammatory Myopathies Patients In Hong Kong Iris Yan Ki Tang Comparison of clinical and laboratory differences between Thai SSc patients with myocardial edema and fibrosis determined by cMRI: preliminary report Suparaporn Wangkaew Clinical heterogeneity in patients with anti-synthetase antibodies Shintaro Yamamoto
0900-1030	Plenary session 4
0900-1030	Chairpersons: Laniyati Hamijoyo and Sandra Navarra Future direction of optimal treatment in SLE Eric Morand Charting the Enigmatic Course of Lupus: Discovering New Pathogenesis Pathways and Aiming at Innovative Therapeutic Targets Nan Shen New concepts of lupus nephritis treatment CC Mok
1030-1050	BREAK AND POSTER VIEWING
1050-1205	Concurrent sessions
	Hot topics in rheumatoid arthritis Chairpersons: Manathip Osiri and Cho Mar Lwin	Imaging SIG session Chairpersons: Kok Ooi and Phonpen Akarawatcharangura Goo	Highlights in Paediatric Rheumatology Chairpersons: Sumaira Farman and Thaschawee Arkachaisri	Abstract session 11: Systemic lupus erythematosus - basic Chairpersons: Sumaira Farman and Prapaporn Pisitkun
	Advances in biological targets in RA Kazuhiko Yamamoto Should csDMARDs be maintained lifelong after sustained remission? Mu Rong	Ultrasonography in large vessel vasculitis (US LVV) - an update Helen Keen Rheumatology ultrasonography (RUS) training in APLAR – a proposed framework Gavin Lee Ultrasonography in Systemic Lupus Erythematosus Farzana Shumy Q&A	Cytokine storms: similarities and dissimilarities between MAS and MIS-C Soamarat Vilaiyuk COVID-19 vaccination in pediatric rheumatic diseases: where are we going forward? Thaschawee Arkachaisri Autoinflammatory diseases in Asian Pacific: are we different? Sulaiman Al-Mayouf	Identification of hub genes that predict response to cyclophosphamide based treatment in proliferative lupus nephritis Sree Nethra Bulusu Unravelling the Complexity of Systemic Lupus Erythematosus (SLE): High-dimensional Interrogation of the adult and paediatric patient immunomes Katherine Nay Yaung Increased proportion of ICOS-expressing follicular helper1 CD4+T cells is associated with high disease activity in systemic lupus erythematosus patients Tipanan Khunsri Expression of interferon- stimulated genes (ISGs) in patients with systemic lupus erythematosus (SLE) for therapy personaliztion and prognosis Zinaida Mutovina Different type I interferon stimulated gene signatures respond differently to the glucocorticoid treatment Koichiro Ohmura Clinical and transcriptomic characteristics in a humanized mouse model for systemic lupus erythematosus personalized medicine Xiaolin Sun Analysis of multicolor flow cytometry on the changes of peripheral blood lymphocyte subsets in elderly patients with systemic lupus erythematosus Chi Sun
1205-1305	BREAK AND POSTER VIEWING
1305-1420	Concurrent sessions
	Updating Imaging in rheumatology Chairpersons: Katy Leung and	ACR / APLAR session Chairperson: Yoshiya Tanaka	Reproductive aspects in rheumatic disease Chairpersons: Chang-Youh Tasi	Abstract session 12: Rheumatoid arthritis Chairperson: Parawee Chevaisrakul
	Imaging modalities for CNS vasculitis evaluation Naoto Tamura Imaging update in spondyloarthritis Ashish Jacob Mathew Imaging update in osteoarthritis Hyun Ah Kim	Therapeutic challenges in gout Kenneth Saag Are the newer treatments in lupus nephritis improving outcomes Sarfaraz Hasni Q&A	Reproductive health in inflammatory arthritis Samar Al-Emadi Reproductive health and biologics Latika Gupta Pregnancy outcomes in SLE Sandra Navarra	Exploring the Impact of Dietary Patterns, Knowledge, and Lifestyle on Joint Health in Elderly Rheumatoid Arthritis Patients in Chongqing, China Xi Zhang Efficacy and Safety of Nipocalimab in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA): the Multicenter/Randomized/Double-blinded/Placebo-controlled/Phase 2a IRIS-RA Study YoungJa Lee Clinical prediction score of sustained remission to methotrexate therapy in patients with early rheumatoid arthritis Sujin Lertwises Efficacy of Methotrexate in Combination with Antioxidant Vitamins (A, C and E) versus Methotrexate alone in Treatment of Rheumatoid Arthritis Md Kamrul Hasan Lohani The Cardiovascular Risk of JAK inhibitors in Treating Rheumatic Disease Alexander Kwan Clinical and patient-reported outcomes for tofacitinib in rituximab-experienced patients with rheumatoid arthritis: results from the CorEvitas Rheumatoid Arthritis Registry Manathip Osiri
1420-1440	BREAK AND POSTER VIEWING
1440-1555	Concurrent sessions
	COVID-19 and beyond Chairpersons: Kichul Shin	Recent understanding and perspective of Sjogren's syndrome Coordinated by the APLAR Sjogren SIG Chairpersons: Sapan Padya	What's new in osteoporosis? Chairpersons: Sumapa Chaiamnuay and Lau Tang Ching	Abstract session 13: Spondyloarthropathies Chairperson: Ajanee Mahakkanukrauh
	Autoimmunity after COVID infection Prapaporn Pisitkun Comparative outcome of patients with rheumatic disease affected by COVID-19 infection Kuo-Tung Tang	GWAS in Sjogren Maureen Rischmueller Recent understanding and perspective of Sjogren's syndrome Atsushi Kawakami Q&A	Epidemiology of bone health in patients with rheumatic diseases Arvind Chopra New evidence of bone safety of glucocorticoids in the treatment of inflammatory rheumatic disease Kenneth Saag Long-term management strategies for osteoporosis: continuous or intermittent? Kosuke Ebina	Placebo-Controlled Efficacy and Safety of Upadacitinib Through One Year in Patients With Non-Radiographic Axial Spondyloarthritis Lai-Shan Tam Ankylosing spondylitis is associated with increased prevalence of valvular heart diseases: a cross-sectional population-based study Mohammad Adawi Efficacy and Safety of Tofacitinib and its comparison with Secukinumab in Axial SpA patients Muhammad Arshad Treat-to-target in spondyloarthritis (SpA): Are there sex-related differential responses? Carson Yip Comparable drug levels and immunogenicity in patients with axial spondyloarthritis treated with adalimumab originator and biosimilar Jin-xian Huang Discriminatory cytokine profile in active ankylosing spondylitis Jin-xian Huang Are Functional Ability, Quality of Life, and Clinical Measurements related to Disease Activity in Patients with Early-treated Axial Spondyloarthritis Tinh Khampaen
1555-1625	Closing Ceremony

Cookie	Duration	Description
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent	1 year	Records the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
elementor	never	This cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
JSESSIONID	session	The JSESSIONID cookie is used by New Relic to store a session identifier so that New Relic can monitor session counts for an application.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Cookie	Duration	Description
__cf_bm	30 minutes	This cookie, set by Cloudflare, is used to support Cloudflare Bot Management.
aka_debug	session	Vimeo sets this cookie which is essential for the website to play video functionality.
bcookie	2 years	LinkedIn sets this cookie from LinkedIn share buttons and ad tags to recognize browser ID.
GN_SESSION_ID_KEY	30 minutes	Gravitec sets this cookie for enabling web push notifications.
GN_USER_ID_KEY	1 year 1 month 4 days	Gravitec sets this cookie for enabling web push notifications.
lang	session	This cookie is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc	1 day	LinkedIn sets the lidc cookie to facilitate data center selection.
player	1 year	Vimeo uses this cookie to save the user's preferences when playing embedded videos from Vimeo.

Cookie	Duration	Description
_ga	2 years	The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_*	1 year 1 month 4 days	Google Analytics sets this cookie to store and count page views.
_ga_8FB98K0V2X	2 years	This cookie is installed by Google Analytics.
_ga_Q3XSFLC6CC	2 years	This cookie is installed by Google Analytics.
_ga_XCTJ9PEH81	2 years	This cookie is installed by Google Analytics.
_gat_gtag_UA_*	1 minute	Google Analytics sets this cookie to store a unique user ID.
_gat_gtag_UA_177203800_1	1 minute	Set by Google to distinguish users.
_gat_UA-*	1 minute	Google Analytics sets this cookie for user behaviour tracking.n
_gat_UA-177203800-1	1 minute	A variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gcl_au	3 months	Provided by Google Tag Manager to experiment advertisement efficiency of websites using their services.
_gid	1 day	Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_uetsid	1 day	This cookies are used to collect analytical information about how visitors use the website. This information is used to compile report and improve site.
CONSENT	16 years 2 months 18 days 19 hours 17 minutes	YouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
vuid	2 years	Vimeo installs this cookie to collect tracking information by setting a unique ID to embed videos to the website.

Cookie	Duration	Description
_fbp	3 months	This cookie is set by Facebook to display advertisements when either on Facebook or on a digital platform powered by Facebook advertising, after visiting the website.
bscookie	2 years	This cookie is a browser ID cookie set by Linked share Buttons and ad tags.
fr	3 months	Facebook sets this cookie to show relevant advertisements to users by tracking user behaviour across the web, on sites that have Facebook pixel or Facebook social plugin.
IDE	1 year 24 days	Google DoubleClick IDE cookies are used to store information about how the user uses the website to present them with relevant ads and according to the user profile.
muc_ads	2 years	Twitter set this cookie to collect visitor navigation data to optimise ad relevance.
MUID	1 year 24 days	Bing sets this cookie to recognize unique web browsers visiting Microsoft sites. This cookie is used for advertising, site analytics, and other operations.
personalization_id	2 years	Twitter sets this cookie to integrate and share features for social media and also store information about how the user uses the website, for tracking and targeting.
test_cookie	15 minutes	The test_cookie is set by doubleclick.net and is used to determine if the user's browser supports cookies.
VISITOR_INFO1_LIVE	5 months 27 days	A cookie set by YouTube to measure bandwidth that determines whether the user gets the new or old player interface.
YSC	session	YSC cookie is set by Youtube and is used to track the views of embedded videos on Youtube pages.
yt-remote-connected-devices	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.
yt-remote-device-id	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.

Cookie	Duration	Description
_uetvid	1 year 24 days	No description available.
AnalyticsSyncHistory	1 month	No description
li_gc	2 years	No description
li_sugr	3 months	No description available.
ln_or	1 day	No description
UserMatchHistory	1 month	Linkedin - Used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.

Preliminary program now available!

Join our mailing list

The countdown is on

Welcome to APLAR 2023